Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSLUMA PET-CT Imaging in Men With PIRADS 2 and 3 Lesions on MRI
NCT07220720Phase 2Recruiting
- Sponsor
- University of Florida
- Start
- Nov 2025
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flotufolastat f 18 in prostate cancer (PCa), sponsored by University of Florida. Primary endpoints: Change in positive predictive value at 12 weeks, Change in negative predictive value at 12 weeks and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
flotufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07220720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220720.